Market Report Source

Overview

Study Goals and Objectives
BCC’s goal in conducting this study was to determine the current status of stem cell technology and its applications and assess its growth potential over a 5-year period from 2007 to 2012. We are particularly interested in the position of adult stem cell technology and applications as compared to the development and applications of embryonic stem cells. Additionally, we are interested in the market potential of emerging breakthroughs in stem cell research such as induced pluripotent stem cells (iPS).

Our key objective is to present a comprehensive analysis of the current state of stem cell research and development (R&D) as well as the current stem cell market and its future direction.

Reasons for Doing the Study
Stem cell technology has been described as the next revolution in medicine. Therapeutic stem cell applications have been proposed to address a wide range of health care needs. We are interested in determining the current state of stem cell technology, where stem cells are currently being applied, and evaluating the potential growth for stem-cell-based applications. In particular, we are interested in discerning the current technological state and potential growth of adult stem-cell-based applications as compared to embryonic-stem-cell-based applications. Additionally, we are interested in looking forward to emerging advancements in stem cell technology and evaluating the potential impact these advancements could have on the development of stem-cell-based products.

Scope of Report
This report encompasses the two major classes of stem cells: adult and embryonic. BCC examined the current state of stem cell technology, focusing on these two major classes as well as emerging breakthroughs in stem cell research and development. Further, BCC evaluated the current stem cell market in the United States (U.S.) and examined the future impact of stem-cell-based technology, presenting forecasts of growth over the next 5 years. Technological issues covering current and emerging stem-cell-based therapeutic applications are also reviewed. Further issues considering stem-cell-based therapeutic research and development and its applications are additionally discussed.

Given the major role that the U.S. plays in the world health care market (both as provider and consumer), this analysis is focused predominantly on the current state of stem cell technology and its applications in the U.S., with some discussion regarding worldwide stem cell technology impact. In addition to technological considerations as well as market issues, we examine governmental (legal and political) as well as social issues regarding the research and development of stem-cell-based therapeutic applications. The present and projected status of stem-cell-based technology is compared for high value applications of cellular therapeutics, engineered tissue for transplantation, and therapeutic stem cell banking. Further, the present and projected status of stem-cell-based therapeutic research applications are projected for high value applications such as cell-based assays, diagnostic tools, and necessary support reagents and materials.

Intended Audience
Given the broad application potential of stem-cell-based technology, the present study will be of interest to the life science industry, in particular, to individuals in the biotechnology, pharmaceutical, and medical device markets. Further, it will be of interest to manufacturers of reagents and tools that support the research and development of stem-cell-based products and services.

Further, this report will of be of interest to professionals presently focused in areas of stem cell research, development, and commercialization as well as those surveying potential stem-cell-based opportunities for investment. Additionally, this report will be of particular interest to health care professionals surveying the potential therapeutic application of stem-cell-based technology and its growth.

Table of Contents

INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
INFORMATION SOURCES
ANALYST CREDENTIALS
RELATED REPORTS
BCC ONLINE SERVICES
DISCLAIMER

SUMMARY

OVERVIEW
HISTORICAL REVIEW OF STEM CELL BIOLOGY
HISTORY OF STEM CELL BIOLOGY
EARLY OBSERVATION AND CLASSIFICATIONS
STEM CELL CLASSIFICATION
Derivation of Human Tissue Types during Development from Embryonic Stem Cells
Derivation of Human Tissue Following Maturation from Adult Stem Cells
STEM CELL CONCEPTS IN HEALTH CARE
INITIAL STEM CELL ISOLATION AND CHARACTERIZATION
EARLY CELL-BASED THERAPEUTICS
Xeno Transplants
Blood Transfusions and Bone Marrow Transplantation
AREAS OF HEALTH CARE NEED AND STEM CELLS
DISEASE- AND DEGENERATION-RELATED HEALTH CARE NEED
ORGAN TRANSPLANTATION-RELATED HEALTH CARE NEED
CANCER- AND GENETIC DISORDER-RELATED HEALTH CARE NEED
INFECTIOUS DISEASE-RELATED HEALTH CARE NEED
HEALTH CARE NEED AND COSTS
CURRENT STATE OF REGENERATIVE MEDICINE
STEM CELL CLASSIFICATION BASED ON SOURCE
Embryonic Stem Cells
Adult (and Progenitor) Stem Cells
STEM CELL CLASSIFICATION BASED ON DIFFERENTIATION POTENTIAL
Pluripotent Stem Cell Differentiation Potential
Multipotent Stem Cell Differentiation Potential
Unipotent Stem Cell Differentiation Potential
DYNAMICALLY EVOLVING AREAS IN STEM CELL BIOLOGY
CLONAL STEM CELLS LINES IN NONHUMAN PRIMATES
EMBRYONIC STEM CELL LINES DERIVED FROM INNER CELL MASS OF VIABLE EMBRYOS
STEM CELLS FROM NEONATAL FLUID
ADULT STEM SOURCING/NICHES
SOURCES
DISEASE-SPECIFIC EMBRYONIC STEM CELL LINES
ADULT STEM CELL REPROGRAMMING
PERSONALIZED HEALTH CARE
CELL-BASED THERAPEUTICS
Using Embryonic-derived Stem Cells
Using Adult/Progenitor-derived Stem Cells
ENGINEERED TISSUE FOR TRANSPLANTATION
Using Embryonic-derived Stem Cells
Using Adult Stem Cells (and Progenitor Cells)
THERAPEUTIC STEM CELL BANKING
STEM-CELL-BASED BIOMEDICAL RESEARCH
MARKETS FOR STEM-CELL-BASED CELLULAR THERAPEUTICS
HEALTH CARE NEED AND THE APPLICATION OF STEM CELLS
Cardiovascular System-related Clinical Stem Cell Applications
Nervous System-related Clinical Stem Cell Applications
Skeletal/Muscular System-related Clinical Stem Cell Applications
Whole Organ (Tissue) System-related Clinical Stem Cell Applications
Stem-cell-related Cancer and Clinical Applications
Infectious Disease/Cancer (General) and Clinical Applications
GOVERNMENT REGULATIONS AND THE USE OF STEM CELLS IN RESEARCH AND THERAPEUTIC APPLICATIONS
GOVERNMENT REGULATION OF THE APPLICATION OF STEM-CELL-BASED THERAPEUTICS
GOVERNMENT REGULATION OF THE APPLICATION OF STEM-CELL-BASED RESEARCH
FUTURE IMPACT OF STEM CELLS ON UNMET HEALTH CARE NEED
STEM CELL TECHNOLOGY IN THE REGENERATIVE MEDICINE MARKET
INTRODUCTION TO STEM CELLS TECHNOLOGY IN REGENERATIVE MEDICINE MARKET
STEM CELLS IN CELLULAR THERAPEUTICS
Stem Cells in Cellular Therapeutics towards Engineering Tissue in Vitro for Transplantation
THERAPEUTIC STEM CELL BANKING
INTRODUCTION TO STEM CELLS TECHNOLOGY IN THERAPEUTIC-RELATED RESEARCH
STEM CELL TECHNOLOGY IN CELL-BASED ASSAYS AND DIAGNOSTIC RESEARCH APPLICATIONS
THERAPEUTIC STEM-CELL-RELATED RESEARCH SUPPORT
FACTORS DRIVING AND INHIBITING APPLICATION OF STEM CELL TECHNOLOGY

MARKETS BY TYPES OF APPLICATIONS
INTRODUCTION TO STEM-CELL-THERAPEUTIC-BASED APPLICATIONS
STEM CELL APPLICATIONS: REGENERATIVE MEDICINE
Stem Cell Applications Specifically by Tissue Type
Stem Cell Applications Specifically by Organ System Type
Stem Cell Applications in Infectious Disease, Genetic Disorders, and Cancer-related
STEM CELL APPLICATIONS IN RESEARCH AND DEVELOPMENT
Stem Cell Applications in Academic Research
Stem Cell Applications in Biotechnology and Medical Device Research
Stem Cells in Pharmaceutical Research

STEM CELL TECHNOLOGY AND DEVELOPMENT
STEM CELL PRODUCTION
STEM CELL ACQUISITION
CHARACTERIZATION AND EXPANSION
MAINTENANCE AND STORAGE
STEM CELL PRODUCTION ECONOMICS
NOVEL STEM CELL PRODUCTION DEVELOPMENTS
ISOLATION AND ENGINEERING
NOVEL DEVELOPMENTS IN THE PRODUCTION OF ADULT STEM CELLS
NOVEL DEVELOPMENTS IN THE PRODUCTION OF EMBRYONIC STEM CELLS
LEADERS IN STEM CELL RESEARCH DEVELOPMENT
ACADEMIC RESEARCH AND DEVELOPMENT LEADERS
Academic Stem Cell Research and Development Scientists
George Q. Daley, MD, Ph.D
Kevin Eggan, Ph.D
Doug Melton, Ph.D
Amy Wagers, Ph.D
Robert Langer, Sc.D
Irving Weissman, MD
Stuart Orkin, MD
Joseph Vacanti, MD
Kenneth Chien, MD, Ph.D
Rudolf Jaenisch, MD
Daniel Tenen, MD
Konrad Hochedlinger, Ph.D.
Paul Matsudaira, Ph.D
Anthony Atala, MD
Elaine Fuchs, Ph.D.
David J. Mooney, Ph.D.
James A. Thomson, Ph.D
Shinya Yamanaka, MD, Ph.D.
Kacey G. Marra, Ph.D
Gordon Keller, Ph.D
Johnny Huard, Ph.D
Hans Keirstead, Ph.D.
Shoukhrat Mitalipov, Ph.D.
Gordon Keller, Ph.D
INDUSTRY RESEARCH AND DEVELOPMENT LEADERS
TECHNOLOGY PATENT ANALYSIS
GENERAL TRENDS
TRENDS BY COUNTRY
TRENDS BY COMPANIES

STEM CELL INDUSTRY STRUCTURE
DRIVING FORCES IN STEM-CELL-BASED INDUSTRIES
DRIVING FORCES IN THE HEALTH CARE MARKET
BIOTECHNOLOGY
PHARMACEUTICAL
COMPETITIVE ADVANTAGES IN STEM-CELL-BASED INDUSTRIES
TECHNOLOGY DEVELOPMENT AND UTILIZATION
COST OF NEW PRODUCT DEVELOPMENT, MANUFACTURING, AND LAUNCH
MARKET POSITIONING AND CAPTURE
IMPORTANT SHIFTS IN INDUSTRY
CONTINUOUSLY EVOLVING TECHNOLOGICAL BASE
EFFECTS OF FLUCTUATIONS IN FEDERAL GOVERNMENT AND FOOD AND DRUG ADMINISTRATION REGULATORY FACTORS
Food and Drug Administration Approval Requirements for Implementation of Stem-cell-based Therapeutics
STAGE OF STEM CELL LIFE CYCLE
IMPACT ON EXISTING HEALTH CARE MARKET MAY BE SIGNIFICANT
MAJOR STEM CELL COMPANIES
MAJOR STEM CELL MARKETS
Stem Cell Market Segmentation
Stem Cell Market Forces
Stem Cell Market Forces (Continued)
GENERAL STEM CELL TECHNOLOGY ISSUES
STEM CELL TECHNOLOGY ISSUES BY TECHNOLOGY
TYPE
Embryonic Stem Cells
Adult Stem Cells
STEM CELL COMPANIES PERCENT MARKET SHARE

COMPANY PROFILES
AASTROM BIOSCIENCES, INC
ALDAGEN, INC
ADVANCED CELL TECHNOLOGY, INC
ARTERIOCYTE, INC.
ATHERSYS, INC.
BD BIOSCIENCES
BIO-MATRIX SCIENTIFIC GROUP, INC.
BIOE
BIOHEART, INC
CELGENE CORP
CELLERANT THERAPEUTICS, INC
CELLULAR DYNAMICS INTERNATIONAL, INC
COGNATE BIOSERVICES, INC.
CRYO-CELL INTERNATIONAL, INC.
CYTOMATRIX, LLC
CYTORI THERAPEUTICS, INC
ENDGENITOR TECHNOLOGIES, INC.
FORTICELL BIOSCIENCE, INC.
GERON CORP
HEALTHEUNIVERSE, INC.
INTERNATIONAL STEM CELL CORPORATION
INVITROGEN CORPORATION
MATTEK CORPORATION
MEDISTEM LABORATORIES, INC.
MEDRA, INC
MILLIPORE
MORPHOGENESIS, INC
MG BIOTHERAPEUTICS, LLC
MORAGA BIOTECHNOLOGY CORPORATION
NEOSTEM, INC
NEURALSTEM, INC
NEUROGENERATION
NEURONYX, INC
NUTECH MEDICAL, INC.
NOVOCELL, INC.
OPEXA THERAPEUTICS, INC.
ORGANOGENESIS, INC.
OSIRIS THERAPEUTICS, INC.
PHARMASTEM THERAPEUTICS, INC
PRIMEGEN BIOTECH, LLC
PROGENITOR CELL THERAPY, LLC
REGENETECH, INC
SANERON CCEL THERAPEUTICS, INC.
STEM CELL INNOVATIONS
STEM CELLS, INC
STEM CELL THERAPY INTERNATIONAL CORP
STEMCELL PHARMA, INC.
STEMCYTE, INC
STEMEDICA CELL TECHNOLOGIES, INC
TENGION, INC
THERADIGM, INC
THERMOGENESIS CORP
VESTA THERAPEUTICS, INC.
VIACELL, INC
VIACORD
VISTAGEN THERAPEUTICS, INC.
VITRO DIAGNOSTICS, INC.

INTERNATIONAL ASPECTS OF REGENERATIVE MEDICINE/STEM CELL MARKET

REFERENCES

APPENDIX A — ABBREVIATIONS

APPENDIX B — GLOSSARY

APPENDIX C – STEM CELL PATENTS, 2000-2008

LIST OF TABLES
SUMMARY TABLE U.S. MARKET FOR STEM CELLS IN REGENERATIVE MEDICINE REVENUE, THROUGH 2012 ($ MILLIONS)
TABLE 1 DERIVATION OF HUMAN TISSUE TYPES DURING DEVELOPMENT
TABLE 2 STEM CELL CLASSIFICATION BASED ON DIFFERENTIATION POTENTIAL
TABLE 3 ADULT STEM CELL TYPES AND POTENTIAL TISSUE SOURCES
TABLE 4 THE NATIONAL INSTITUTES OF HEALTH STEM CELL RESEARCH FUNDING, 2004-2009 ($ MILLIONS)
TABLE 5 THE NATIONAL INSTITUTES OF HEALTH HUMAN EMBRYONIC STEM CELL REGISTRY
TABLE 6 STATES FUNDING STEM-CELL-RELATED RESEARCH
TABLE 7 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN REGENERATIVE MEDICINE, THROUGH 2012 ($ MILLIONS)
TABLE 8 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, THROUGH 2012 ($ MILLIONS)
TABLE 9 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, THROUGH 2012 ($ MILLIONS)
TABLE 10 PROJECTED U.S. GROWTH TREND FOR STEM-CELLRELATED THERAPEUTIC RESEARCH ($ MILLIONS)
TABLE 11 PROJECTED U.S. GROWTH TREND FOR STEM-CELLRELATED CELL-BASED ASSAYS/DIAGNOSTICS THERAPEUTIC RESEARCH BY SEGMENT, THROUGH 2012 ($ MILLIONS)
TABLE 12 FACTORS DRIVING AND INHIBITING THE APPLICATION OF STEM-CELL-BASED THERAPEUTICS
TABLE 14 STEM CELL TECHNOLOGY AREAS OF APPLICATION WITHIN THE LIFE SCIENCES
TABLE 15 HIGHLIGHTED STEM CELL RESEARCH PUBLICATIONS, 2005-2008
TABLE 16 STEM CELL PATENT TRENDS, 2000-2008
TABLE 17 STEM CELL PATENT COUNTRY CODES, 2000-2008
TABLE 18 STEM CELL PATENT TRENDS BY COUNTRY, 2000-2008
TABLE 19 STEM CELL PATENT TRENDS BY COUNTRY OF PATENTS, 2000-2008 (%)
TABLE 20 STEM CELL PATENT TRENDS BY COMPANIES ASSIGNED TWO OR MORE PATENTS, 2000-2008
TABLE 21 RESTRICTIONS ON STEM CELL RESEARCH BY STATE
TABLE 22 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS, 2000-2008
TABLE 23 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS FUNDED BY INDUSTRY, 2000-2008
TABLE 24 STEM CELL CLINICAL TRIALS RELATED TO CANCER (PERIPHERAL BLOOD/BONE MARROW TRANSPLANTATION), 2000-2008 (%)
TABLE 25 MARKET SHARE OF STEM CELL THERAPEUTICS (AND BANKING) COMPANIES, 2005-2007 (%)
TABLE 26 AASTROM BIOSCIENCES, INC. STEM CELL CLINICAL TRIALS
TABLE 27 AASTROM BIOSCIENCES, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 28 ALDAGEN, INC. STEM CELL CLINICAL TRIALS
TABLE 29 ALDAGEN, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 30 ADVANCED CELL TECHNOLOGY, INC. STEM CELL CLINICAL TRIALS
TABLE 31 ADVANCED CELL TECHNOLOGY, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 32 ARTERIOCYTE, INC. STEM CELL CLINICAL TRIALS
TABLE 33 BIOE STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 34 BIOHEART, INC. STEM CELL CLINICAL TRIALS
TABLE 35 BIOHEART, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 36 CELLERANT THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
TABLE 37 CELLERANT THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 38 COGNATE BIOSERVICES, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 39 CYTOMATRIX, LLC STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 40 CYTORI THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
TABLE 41 CYTORI THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 42 FORTICELL BIOSCIENCE, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 43 GERON CORP STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 44 HEALTHEUNIVERSE, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 45 MATTEK CORP STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 46 MEDISTEM LABORATORIES, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 47 MORPHOGENESIS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 48 NEOSTEM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 49 NEURALSTEM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 50 NEURONYX, INC. STEM CELL CLINICAL TRIALS
TABLE 51 NEURONYX, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 52 NOVOCELL, INC STEM CELL CLINICAL TRIALS
TABLE 53 NOVOCELL, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 54 OPEXA THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
TABLE 55 ORGANOGENESIS, INC. STEM CELL CLINICAL TRIALS
TABLE 56 ORGANOGENESIS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 57 OSIRIS THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
TABLE 58 OSIRIS THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 59 PHARMASTEM THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 60 REGENETECH, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 61 STEM CELL INNOVATIONS STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 62 STEM CELLS, INC. STEM CELL CLINICAL TRIALS
TABLE 63 STEM CELLS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 64 TENGION, INC. STEM CELL CLINICAL TRIALS
TABLE 65 THERADIGM, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 66 VESTA THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 67 VIACELL, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 68 VISTAGEN THERAPEUTICS, INC. STEM CELL CLINICAL TRIALS
TABLE 69 VISTAGEN THERAPEUTICS, INC. STEM CELL PATENTS ISSUED OR EXCLUSIVELY LICENSED
TABLE 70 LEADING GLOBAL REGENERATIVE MEDICINE/STEM CELL COMPANIES
TABLE 71 STEM CELL PATENTS BETWEEN THE YEARS 2000 AND 2008

LIST OF FIGURES
SUMMARY FIGURE U.S. MARKET FOR STEM CELLS IN REGENERATIVE MEDICINE REVENUE, 2005-2012 ($ MILLIONS)
FIGURE 1 FLOW DIAGRAM OF HUMAN DEVELOPMENT PROCESS
FIGURE 2 THE NATIONAL INSTITUTES OF HEALTH HUMAN STEM CELL RESEARCH FUNDING, 2004-2009 ($ MILLIONS)
FIGURE 3 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN REGENERATIVE MEDICINE, 2005-2012 ($ MILLIONS)
FIGURE 4 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN CELLULAR THERAPEUTICS
FIGURE 5 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, 2005-2012 ($ MILLIONS)
FIGURE 6 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN ENGINEERING TISSUE FOR TRANSPLANTATION
FIGURE 7 FLOW DIAGRAM FOR PROCESS OF THERAPEUTIC BANKING OF STEM CELLS
FIGURE 8 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, 2005-2012 ($ MILLIONS)
FIGURE 9 PROJECTED U.S. GROWTH TREND FOR STEM-CELLRELATED THERAPEUTIC RESEARCH, 2005-2012 ($ MILLIONS)
FIGURE 10 PROJECTED U.S. GROWTH TREND FOR STEM-CELLRELATED CELL-BASED ASSAYS/DIAGNOSTICS THERAPEUTIC RESEARCH BY SEGMENT, 2005-2012 ($ MILLIONS)
FIGURE 11 FLOW DIAGRAM FOR PROCESS OF STEM CELL PRODUCTION
FIGURE 12 STEM CELL PATENT TRENDS, 2000-2008
FIGURE 14 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS, 2000-2008
FIGURE 15 TOTAL NUMBER OF STEM CELL CLINICAL TRIALS FUNDED BY INDUSTRY, 2000-2008
FIGURE 16 STEM CELL CLINICAL TRIALS RELATED TO CANCER (PERIPHERAL BLOOD/BONE MARROW TRANSPLANTATION), 2000-2008 (%)